Compare Quest Diagnostics Inc (DGX) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs KB Financial Group, Inc. — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while KB Financial Group, Inc. trades at $123.07 (market cap $42.62B). The key difference: KB Financial Group, Inc. is the larger of the two by market cap, and KB Financial Group, Inc. pays the higher dividend (2.71%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and KB Financial Group, Inc. for 33 Days on average.
| DGX | KB | |
|---|---|---|
Market Cap | $25.48B | $42.62B |
Volume | 941,866 | 164,291 |
Sector | Health | Financials |
52-Week High | $247.45 | $132.88 |
52-Week Low | $173.49 | $77.50 |
Typical Hold Time | 56 Days | 33 Days |
Enterprise Value | $31.23B | $215.53T |
Dividend Yield | 1.49% | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
KB Financial Group (KB) trades at $123.07, down 1.33% today, with mixed technical signals showing a neutral overall trend. The company demonstrates strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $3.79 beating expectations of $3.51. Revenue growth has been steady from $17.8T in 2022 to $21.2T in 2025, with net income margins improving to 27.47%. Analyst sentiment is mixed with 33% buy ratings and 67% hold recommendations.
KB presents a compelling value opportunity with a P/E of 9.68 and P/B of 0.94 below industry averages. The main investment thesis centers on continued earnings momentum and South Korean market outperformance, though risks include banking sector volatility and interest rate sensitivity. The stock's current valuation discount to intrinsic value suggests potential upside if earnings growth persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
